Davos Alzheimer's Collaborative Inc

What it reported doing in 2025

The davos alzheimer's collaborative's global cohort development program focuses on building a diverse and sustainable network of cohorts to advance alzheimer's disease (ad) and related dementias (adrd) research. This includes partnerships such as the collaboration with aga khan university in nairobi, kenya, where cognitive tests, saliva-based polygenic risk scores, and digital cognitive assessments are being validated in east african populations to create a clinical trial-ready cohort. In south korea, dac has acquired blood samples from 300 participants in a highly characterized cohort, advancing the validation of blood-based biomarkers (bbms) for global use. The project also includes access to 1,000 blood samples from a long-standing cohort in the latam/caribbean region for ad blood biomarker validation, as well as a large-scale clinical trial recruitment effort in the dominican republic, with over 14,000 participants across urban and rural settings.further expanding global research, dac is developing scalable approaches in egypt for early detection, monitoring, and risk reduction of ad, while in india, the "eye-dea study" is using cataract surgery clinics to assess ocular, speech, and olfactory biomarkers related to cognitive impairment. In chile, dac is collecting a wide range of data from a 9,000-person cohort to generate local validation data for blood biomarkers and digital cognitive assessments, particularly focusing on the impact of pesticide use and exposure to neurotoxins. These efforts are helping to ensure that ad research is inclusive of diverse populations and adaptable to local settings, with the aim of improving early detection, diagnosis, and treatment on a global scale.

Financial Efficiency

• Mission deployment rate: 100%; rating input score 100
• Program expense ratio: 92.2%; rating input score 92
• Fundraising efficiency: $16.19 raised per $1 spent on fundraising; rating input score 48; 48th percentile among comparable filings

Transparency & Controls

• Consistency checks: 100%; rating input score 100; 64th percentile among comparable filings
• Pay-setting controls: Limited
• Foreign activity oversight: 3 of 8 controls in place; rating input score 38
  • Claims monitoring procedures: Pass
  • Requires narrative reports: Fail
  • Conducts field audits: Fail
  • May suspend future funding: Fail
  • Requires financial reports: Pass
  • Conducts site visits: Fail
  • Requires grant agreements: Pass
  • May require repayment: Fail
• Grant itemization coverage: 99.8%; rating input score 100; 47th percentile among comparable filings
• Major donor itemization: Yes; rating input score 100
• Related-party transparency: Yes; rating input score 100

Accountability

• Independent voting board: 66.7%; rating input score 67; 10th percentile among comparable filings
• Governance controls: 7 of 7 controls in place; rating input score 100
  • Conflict-of-interest policy: Pass
  • Whistleblower policy: Pass
  • Document-retention policy: Pass
  • CEO compensation review process: NotApplicable
  • Other executive compensation review process: NotApplicable
  • Form 990 shared with the board: Pass
  • Board meeting minutes documented: Pass
  • Audit committee oversight: Pass
  • Independent financial-statement audit: Pass

Sustainability

• Operating margin: -29%; rating input score 2; 2nd percentile among comparable filings
• Total-asset coverage ratio: 0.53; rating input score 13; 13th percentile among comparable filings
• Liabilities to assets ratio: 0.07; rating input score 72; 72nd percentile among comparable filings
• Officer compensation ratio: 0%; rating input score 96; 96th percentile among comparable filings

Growth

• Program expense growth: 23% per year; rating input score 100; 90th percentile among comparable filings
• Revenue growth: 8.7% per year; rating input score 100; 67th percentile among comparable filings
• Asset growth: -15.9% per year; rating input score 0; 0th percentile among comparable filings